Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 Months

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 15, 2025

Primary Completion Date

December 23, 2025

Study Completion Date

December 23, 2025

Conditions
Pediatric Gastroesophageal Reflux Disease
Interventions
DRUG

Dexlansoprazole

Dexlansoprazole capsules

Trial Locations (22)

21218

Johns Hopkins University School Of Medicine, Baltimore

40202

University of Louisville, Louisville

43606

Promedica Toledo Children's Hospital, Toledo

48532

Michigan Pediatric GI Center, Flint

58260

Centro de Investigacion Clinica Chapultepec S.A. de C.V., Morelia

64000

Accelerium S. de R.L. de C.V., Monterrey

75309

Assaf Harofeh M.C, Rishon LeZiyyon

76104

Cook Children's Medical Center, Fort Worth

80131

"Azienda Ospedaliera Universitaria Federico II", Napoli

90027

Children's Hospital Los Angeles, Los Angeles

4920235

Schneider Children's Medical Center, Petah Tikva

5262000

Sheba Medical Center, Ramat Gan

9112001

Hadassah University Hospital - Ein Kerem, Jerusalem

00161

Umberto I Pol. di Roma-Universita di Roma La Sapienza, Roma

00165

Ospedale Pediatrico Bambino Gesu, Roma

00168

Policlinico Universitario Agostino Gemelli, Roma

07020

Centro de Investigacion Clinica Acelerada, S.C., Mexico City

85-168

Szpital Uniwersytecki nr 2 im.dr J. Biziela, Bydgoszcz

30-663

Uniwersytecki Szpital Dzieciecy w Krakowie, Krakow

20-093

Uniwersytecki Szpital Dzieciecy w Lublinie, Lublin

35-301

Szpital Wojewodzki nr 2 w Rzeszowie, Rzeszów

04-730

"Instytut Pomnik - Centrum Zdrowia Dziecka", Warsaw

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY